Kenneth Holbourn suggested that standardizing more of downstream purification could reduce process development complexity and support a faster transition into clinical manufacturing. Monoclonal antibodies (mAbs) have benefited from decades of manufacturing experience and increasingly standardized production processes. But biologics pipelines are also becoming more diverse, encompassing antibody fragments, fusion proteins, enzymes, cytokines and other recombinant […]